Fangda represented Kyowa Kirin on the deal. Kyowa Kirin, a global leading R&D company for innovative drugs, has reached a series of asset restructuring arrangements with...
You must be a Standard 1 Year member to access this content.
Fangda advised QuantumPharm on the offering. QuantumPharm Inc. was successfully listed on the Main Board of the Stock Exchange of Hong Kong Limited and launched a globally...
You must be a Standard 1 Year member to access this content.
Fangda advised AnHeart Therapeutics on the deal. Nuvation Bio Inc., a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and...
You must be a Standard 1 Year member to access this content.
Fangda represented Kirin Holdings Company on the deal. Kirin Holdings Company executed the sale of its entire 40% stake in its joint venture with China Resources for...
You must be a Standard 1 Year member to access this content.
